

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/B3D5407AD78EN.html>

Date: January 2018

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: B3D5407AD78EN

Abstracts

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2018

SUMMARY

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 21 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 5, 9 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Prostate Cancer, Pancreatic Cancer, Bladder Cancer, Melanoma, Autoimmune Disorders, Bone Metastasis, Colorectal Cancer, Ovarian Cancer, Breast

Cancer, Colon Carcinoma, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)

The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects

The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's

most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development

Biomics Biotechnologies Co Ltd

Bioneer Corp

Boehringer Ingelheim GmbH

Immunovaccine Inc

MimiVax LLC

Optimum Therapeutics LLC

Polyplus-Transfection SA

Stemline Therapeutics Inc

tella Inc

Vaxeal Holding SA

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles

Antibody to Target Survivin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGA-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1644 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1740 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPX-Survivac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Survivin for Oncology and Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UC-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Colon Carcinoma and Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Survivin for Autoimmune Diseases, Glioblastoma Multiforme and Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Survivin for Breast Cancer and Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones

Featured News & Press Releases

Dec 05, 2017: Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

Dec 05, 2017: Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

Nov 16, 2017: Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

Nov 08, 2017: Immunovaccine Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck's Checkpoint Inhibitor Pembrolizumab in DLBCL

Aug 07, 2017: FDA Awards Orphan Status to Brain Cancer Vaccine Developed at Roswell Park Cancer Institute

May 16, 2017: Immunovaccines Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug

Apr 11, 2017: Princess Margaret Cancer Center Receives Health Canada Clearance to Begin Investigator-Sponsored Phase 2 Ovarian Cancer Study Evaluating Immunovaccine's DPX-Survivac with Merck's Pembrolizumab

Mar 29, 2017: Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX-Survivac in Combination with Epacadostat

Feb 21, 2017: Stemline Therapeutics Provides Update on SL-701

Feb 06, 2017: Immunovaccines Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in Ovarian Cancer in Combination With Approved Anti-PD-1 Drug

Nov 22, 2016: The European Medicines Agency Grants Orphan Drug Designation Status to Immunovaccine's DPX-Survivac in Ovarian Cancer

Nov 21, 2016: Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 21st Annual Meeting of the Society of Neuro-Oncology (SNO)

Sep 08, 2016: Immunovaccine Announces Dosing of First Patient in Phase 1b Clinical Trial for DPX-Survivac in Combination with Incyte's IDO1 Enzyme Inhibitor Epcadostat

Aug 25, 2016: Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program with DPX-Survivac in Ovarian Cancer

May 31, 2016: Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
Pipeline by Bioneer Corp, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Immunovaccine Inc, H1 2018
Pipeline by MimiVax LLC, H1 2018
Pipeline by Optimum Therapeutics LLC, H1 2018
Pipeline by Polyplus-Transfection SA, H1 2018
Pipeline by Stemline Therapeutics Inc, H1 2018
Pipeline by tella Inc, H1 2018
Pipeline by Vaxeal Holding SA, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Biomics Biotechnologies Co Ltd

Bioneer Corp

Boehringer Ingelheim GmbH

Immunovaccine Inc

MimiVax LLC

Optimum Therapeutics LLC

Polyplus-Transfection SA

Stemline Therapeutics Inc

tella Inc

Vaxeal Holding SA

I would like to order

Product name: Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/B3D5407AD78EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3D5407AD78EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

